The influence of EDTA on B. glabrata has been investigated. Newly hatched snails were exposed to concentrations of EDTA from 1 to 64 ppm, and young (diameter of 6 mm) snails to concentrations of 50, 80 and 100 ppm, for periods of 90 days. Fifty percent reduction of egg productivity has been caused by concentration of 16 ppm of EDTA while 50% of mortality has occurred at about 70 ppm. The calcium and iron content both in treated and non-treated young snails have been estimated by atomic absorption photometry. The uptake of calcium was 40, 83 and 90% less for calcium and 37, 77 and 81% less for iron as compared with the untreated group. The calcium content of the shell was 5--15 times greater than that of the soft body, while the iron content of those two parts was in the proportion of 1:1. These proportions were maintained constant in the treated and non-treated groups. The interference of increasing concentrations of EDTA has resulted in the proportional reduction of growth-rate, reproduction rate and of longevity of the exposed snails.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: Neurofilament Light Chain (NfL) is a blood biomarker of axonal injury and neurodegeneration that can be used in a variety of neurological disorders. Despite the potential clinical use of plasma NfL across multiple neurological disorders, there is increasing evidence that underlying comorbidities such as renal impairment associated with chronic kidney disease (CKD) and cardiovascular diseases can increase NfL concentrations. The objective of this study was to determine the relationship between plasma NfL concentrations and renal function (CKD staging) in individuals without known neurological conditions.
View Article and Find Full Text PDFBackground: The analytical performance characteristics for the plasma Glial Fibrillary Acidic Protein (GFAP) immunoassay currently under development on Beckman Coulter, Inc. Access2™ and DxI9000™ analyzers is described. Blood GFAP levels may be indicative of the extent of neurologic injury in diseases such as TBI and stroke and maybe used as a marker of disease progression in other diseases such as multiple sclerosis.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Background: Plasma pTau217 (tau phosphorylated at threonine 217) assays will expand access to screening for Alzheimer's disease (AD). However, clinical interpretation is not well-established, particularly during the preclinical window when interventions may be most effective. Using plasma samples from primarily late-midlife, cognitively unimpaired Wisconsin Registry for Alzheimer's Prevention (WRAP) and Wisconsin Alzheimer's Disease Center (WADRC) participants, we investigated pTau217 agreement with amyloid and tau PET then compared trajectories between participants grouped by baseline pTau217.
View Article and Find Full Text PDFBackground: Hyperphosphorylated Tau is a pathologic hallmark of the neurofibrillary tangles in Alzheimer's Disease (AD). p-Tau is a promising blood-based biomarker in AD research, drug development, diagnosis, disease monitoring, and patient care. Several assays for p-Tau in plasma have been previously described, however there is a need to make this test easily available to the clinical laboratories around the world and more accessible to the patients and the clinicians.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Gothenburg, Sweden.
Background: With no effective therapy targeting the pathology of genetic frontotemporal lobar degeneration (FTLD), there is a need for easily accessible biomarkers enabling the development of therapeutic agents and for clinical diagnostics. Thus, we aimed to investigate the proteomic changes in plasma of progranulin (GRN) mutation carriers using a novel ultrasensitive antibody-based platform.
Methods: We cross-sectionally evaluated carriers of pathogenic GRN mutations (GRN+) and age- and sex-matched cognitively healthy non-carriers (GRN-) from the University of Brescia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!